Skip to main content

Table 5 Disease-specific survival in patients with resectable high-grade salivary gland cancers (n = 103)

From: Treatment outcomes in metastatic and localized high-grade salivary gland cancer: high chance of cure with surgery and post-operative radiation in T1–2 N0 high-grade salivary gland cancer

  Univariate model Multivariate model
HR 95% CI P HR 95% CI P
 Age (years) 1.012 0.980–1.045 0.464    
 Gender (Male/Female) (83/20) 2.325 0.697–7.756 0.170    
 Primary site
  Parotid gland (69) 1 (Ref.)      
  Non-parotid gland (34) 1.409 0.644–3.081 0.390    
 TN categories
  T3–4/T1–2 (45/58) 2.011 0.919–4.403 0.080 0.744 0.285–1.938 0.544
  N1–3/N0 (48/55) 6.115 2.509–14.903 < 0.001 10.211 3.485–29.919 < 0.001
 Pathological diagnosis
  Salivary duct carcinoma (67) 1 (Ref.)      
  Squamous cell carcinoma, primary (9) 0.627 0.145–2.718 0.533    
  Adenoid cystic carcinoma, solid type (8) 1.557 0.457–5.308 0.479    
  Mucoepidermoid carcinoma, high-grade (7) 0.541 0.072–4.069 0.550    
  Adenocarcinoma, high-grade (6) 0.439 0.058–3.302 0.424    
  Others (6) 1.978 0.455–8.604 0.363    
 Treatment modalities
  Surgery (13) 1 (Ref)    1 (Ref)   
  Surgery + radiation (62) 1.266 0.377–4.248 0.702 0.742 0.207–2.655 0.646
  Surgery + radiation + chemotherapy (28) 0.433 0.087–2.155 0.307 0.121 0.022–0.677 0.016
  Surgery for primary tumor (R1/R0) (6/97) 0.045 0.000–39.169 0.369    
  Neck dissection/no neck dissection (72/31) 1.871 0.780–4.488 0.161    
 Pathological risk factors
  Perineural invasion (Y/N) (13/90) 0.042 0.000–12.297 0.274    
  Lymphovascular invasion (Y/N) (16/87) 0.043 0.000–20.431 0.317    
  Extra-parenchymal extension (Y/N) (45/58) 2.156 0.979–4.750 0.057    
  Extra-capsular spread (Y/N) (26/77) 2.547 1.065–6.092 0.036 1.363 0.509–3.649 0.538
  1. Abbreviation:
  2. HR hazard ratio, CI confidence interval
  3. R1 resection: Cancer cells present at the resection margin, R0 resection: Cancer cells absent at the resection margin
  4. Others (Pathological diagnosis): Atypical high-grade carcinoma, high-grade carcino-sarcoma, poorly differentiated carcinoma
  5. Y: presence, N: absence